Daiichi Sankyo's CEO on the Delayed Earnings and the Price of Success
# Sandoz# Delayed Earnings# Cancer Treatment
Key Points
- Daiichi Sankyo is aiming for a global top-five position in oncology by 2035.
- Success with the cancer drug Enhertu is funding faster drug development and structural reform.
- This spring the company postponed both its mid-term plan briefing and its earnings release; the president discusses that and why compensating partners was the price of success.
Analysis
Sandoz's CEO candidly discusses the reasons behind the delayed earnings, offering a rare peek into Japan's corporate landscape for English-speaking readers. This transparency is crucial in building trust and long-term relationships with stakeholders.
The company's push to accelerate new drug development and business restructuring following the success of Enhertu provides valuable insights for pharmaceutical companies globally facing similar challenges in balancing current product lines with future innovations.